Building Once, Validating Forever: Why Scalable CQV Is the Future-Proof Strategy Life Sciences Manufacturers Can’t Ignore – Scalability is the difference between a validation program that becomes a growing liability and one that becomes a strategic asset as your operation expands.
The Future of the Modern Laboratory Is Here: Introducing Mivado GlobalPerformance’s AI-Driven LIMS – In today’s fast-paced scientific and industrial landscape, laboratories are under more pressure than ever to deliver faster results and maintain airtight compliance.
Tagged : AI, AI-LIMS, APQR, Biopharma, Biopharmaceutical, Compliance, Digital Transformation, Digitalization, GxP, Health Canada, LIMS, Quality 4.0
Risk Evaluation in Biopharmaceutical Technology Transfer: Why a Risk-Based Approach Is Essential for GMP Success. Successful biopharmaceutical technology transfer depends on more than process knowledge.
Tagged : Biopharmaceutical, Compliance, GxP, MSAT, QRM, Quality 4.0, Risk Management, Technology Transfer
Drafting Perfect 483 Responses: The New FDA Guidelines Explained. FDA Form 483 observations are issued when investigators identify conditions that may violate cGMP requirements.
Beyond Documentation: Solving the Tacit Knowledge Gap in Pharmaceutical Tech Transfer: This article discuss why Your Documentation Is Not Enough and How to Institutionalize Expert Know-How. Visit us for more…